U.S. markets open in 8 hours 59 minutes

Innoviva, Inc. (INVA)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
10.85+0.29 (+2.75%)
At close: 1:00PM EST

Innoviva, Inc.

1350 Old Bayshore Highway
Suite 400
Burlingame, CA 94010
United States
650 238 9600
http://www.inva.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees5

Key Executives

NameTitlePayExercisedYear Born
Ms. Marianne Zhen CPAChief Accounting Officer426.92kN/A1969
Mr. Pavel Raifeld C.F.A.Chief Exec. OfficerN/AN/AN/A
Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Innoviva, Inc. engages in the development and commercialization of pharmaceuticals. The company has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA, and VI; and TRELEGY ELLIPTA, a once-daily combination medicine consisting of an ICS, LAMA, and LABA. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.

Corporate Governance

Innoviva, Inc.’s ISS Governance QualityScore as of November 1, 2019 is 5. The pillar scores are Audit: 2; Board: 4; Shareholder Rights: 4; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.